Company Filing History:
Years Active: 2020
Title: Innovations in Cancer Treatment: The Contributions of Jianming Xu
Introduction
Jianming Xu is a notable inventor based in Beijing, China. He has made significant contributions to the field of cancer treatment, particularly in the detection of drug resistance in metastatic colorectal cancer patients. His work is crucial for improving patient outcomes and advancing medical research.
Latest Patents
Jianming Xu holds a patent for a novel method titled "PIK3CA novel mutations detection for diagnosis of acquired cetuximab resistance in metastatic colorectal cancer patients." This patent discloses a kit designed to detect drug resistance to cetuximab, a treatment for metastatic colorectal cancer. The kit includes a substance for identifying gene mutations in Exon 19 of the PIK3CA gene. It is particularly useful for patients who are either about to receive or are currently undergoing cetuximab treatment. The detection of specific mutations, such as K944N, F930S, V955G, V955I, and K966E, can indicate whether a patient is likely to develop drug resistance.
Career Highlights
Jianming Xu is affiliated with the Affiliated Hospital of the Academy of Military Medical Sciences. His work in this institution has allowed him to collaborate with other experts in the field and contribute to groundbreaking research in cancer treatment.
Collaborations
One of his notable coworkers is Yan Wang, with whom he has likely collaborated on various research projects aimed at enhancing cancer treatment methodologies.
Conclusion
Jianming Xu's innovative work in detecting drug resistance in cancer treatment exemplifies the importance of research and development in the medical field. His contributions are vital for improving the effectiveness of treatments for metastatic colorectal cancer patients.